NCT01382654View on ClinicalTrials.gov

Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

Allergic Rhinitis

Interventions

DRUG

epinastine 0.1%

nasal spray 2 sprays to each nostril for a total of 3 doses

DRUG

epinastine 0.1% with taste masking agent

nasal spray 2 sprays to each nostril for a total for a 3 doses

DRUG

epinastine 0.2%

nasal spray 2 sprays to each nostril for a total of 3 doses

DRUG

epinastine 0.2% with taste masking agent

nasal spray 2 sprays to each nostril for a total of 3 doses

DRUG

azelastine 0.1%

nasal spray 2 sprays to each nostril for a total of 3 doses

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01382654 - Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis | Biotech Hunter | Biotech Hunter